|
1
|
Jayson GC, Kohn EC, Kitchener HC and
Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Colombo N, Peiretti M, Parma G, Lapresa M,
Mancari R, Carinelli S, Sessa C and Castiglione M; ESMO Guidelines
Working Group, : Newly diagnosed and relapsed epithelial ovarian
carcinoma: ESMO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 21 Suppl 5:v23–v30. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Foster T, Brown TM, Chang J, Menssen HD,
Blieden MB and Herzog TJ: A review of the current evidence for
maintenance therapy in ovarian cancer. Gynecol Oncol. 115:290–301.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Morgan RJ Jr, Alvarez RD, Armstrong DK,
Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray
HJ, Hakam A, et al: Ovarian cancer, version 2.2013. J Natl Compr
Canc Netw. 11:1199–1209. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shen DW, Pouliot LM, Hall MD and Gottesman
MM: Cisplatin resistance: A cellular self-defense mechanism
resulting from multiple epigenetic and genetic changes. Pharmacol
Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Borley J and Brown R: Epigenetic
mechanisms and therapeutic targets of chemotherapy resistance in
epithelial ovarian cancer. Ann Med. 47:359–369. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Anglicheau D, Muthukumar T and
Suthanthiran M: MicroRNAs: Small RNAs with big effects.
Transplantation. 90:105–112. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu C, Xie S, Song C, Huang L and Jiang Z:
Lin28 mediates cancer chemotherapy resistance via regulation of
miRNA signaling. Hepatogastroenterology. 61:1138–1141.
2014.PubMed/NCBI
|
|
10
|
Niu J, Xue A, Chi Y, Xue J, Wang W, Zhao
Z, Fan M, Yang CH, Shao ZM, Pfeffer LM, et al: Induction of
miRNA-181a by genotoxic treatments promotes chemotherapeutic
resistance and metastasis in breast cancer. Oncogene. 35:1302–1313.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guo Y, Yan K, Fang J, Qu Q, Zhou M and
Chen F: Let-7b expression determines response to chemotherapy
through the regulation of cyclin D1 in glioblastoma. J Exp Clin
Cancer Res. 32:412013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xie T, Huang M, Wang Y, Wang L, Chen C and
Chu X: MicroRNAs as regulators, biomarkers and therapeutic targets
in the drug resistance of colorectal cancer. Cell Physiol Biochem.
40:62–76. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kopczynska E: Role of microRNAs in the
resistance of prostate cancer to docetaxel and paclitaxel. Contemp
Oncol (Pozn). 19:423–427. 2015.PubMed/NCBI
|
|
14
|
Yang G, Jiang O, Ling D, Jiang X, Yuan P,
Zeng G, Zhu J, Tian J, Weng Y and Wu D: MicroRNA-522 reverses drug
resistance of doxorubicin-induced HT29 colon cancer cell by
targeting ABCB5. Mol Med Rep. 12:3930–3936. 2015.PubMed/NCBI
|
|
15
|
Yu J, Lu Y, Cui D, Li E, Zhu Y, Zhao Y,
Zhao F and Xia S: miR-200b suppresses cell proliferation, migration
and enhances chemosensitivity in prostate cancer by regulating
Bmi-1. Oncol Rep. 31:910–918. 2014.PubMed/NCBI
|
|
16
|
Jiang Z, Yin J, Fu W, Mo Y, Pan Y, Dai L,
Huang H, Li S and Zhao J: MiRNA 17 family regulates
cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC.
PloS One. 9:e946392014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Weng H, Huang H, Dong B, Zhao P, Zhou H
and Qu L: Inhibition of miR-17 and miR-20a by oridonin triggers
apoptosis and reverses chemoresistance by derepressing BIM-S.
Cancer Res. 74:4409–4419. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fan X, Liu Y, Jiang J, Ma Z, Wu H, Liu T,
Liu M, Li X and Tang H: miR-20a promotes proliferation and invasion
by targeting APP in human ovarian cancer cells. Acta Biochim
Biophys Sin (Shanghai). 42:318–324. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang Y, Zheng L, Ding Y, Li Q, Wang R,
Liu T, Sun Q, Yang H, Peng S, Wang W and Chen L: MiR-20a induces
cell radioresistance by activating the PTEN/PI3K/Akt signaling
pathway in hepatocellular carcinoma. Int J Radiat Oncol Biol Phys.
92:1132–1140. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jayson GC, Kohn EC, Kitchener HC and
Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Markman M: Current standards of care for
chemotherapy of optimally cytoreduced advanced epithelial ovarian
cancer. Gynecol Oncol. 131:241–245. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M
and Croce CM: Human microRNA genes are frequently located at
fragile sites and genomic regions involved in cancers. Proc Natl
Acad Sci USA. 101:pp. 2999–3004. 2004; View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Farazi TA, Spitzer JI, Morozov P and
Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li N, Yang L, Wang H, Yi T, Jia X, Chen C
and Xu P: MiR-130a and MiR-374a function as novel regulators of
cisplatin resistance in human ovarian cancer A2780 cells. PloS One.
10:e01288862015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Samuel P, Pink RC, Caley DP, Currie JM,
Brooks SA and Carter DR: Over-expression of miR-31 or loss of
KCNMA1 leads to increased cisplatin resistance in ovarian cancer
cells. Tumour Biol. 37:2565–2573. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Song J and Li Y: miR-25-3p reverses
epithelial-mesenchymal transition via targeting Sema4C in
cisplatin-resistance cervical cancer cells. Cancer Sci. 108:23–31.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Raza U, Saatci Ö, Uhlmann S, Ansari SA,
Eyüpoğlu E, Yurdusev E, Mutlu M, Ersan PG, Altundağ MK, Zhang JD,
et al: The miR-644a/CTBP1/p53 axis suppresses drug resistance by
simultaneous inhibition of cell survival and epithelial-mesenchymal
transition in breast cancer. Oncotarget. 7:49859–49877.
2016.PubMed/NCBI
|
|
31
|
Singh R, Yadav V, Kumar S and Saini N:
MicroRNA-195 inhibits proliferation, invasion and metastasis in
breast cancer cells by targeting FASN HMGCR, ACACA and CYP27B1. Sci
Rep. 5:174542015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zuo QF, Cao LY, Yu T, Gong L, Wang LN,
Zhao YL, Xiao B and Zou QM: MicroRNA-22 inhibits tumor growth and
metastasis in gastric cancer by directly targeting MMP14 and Snail.
Cell Death Dis. 6:e20002015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pavelic S Kraljevic, Sedic M, Bosnjak H,
Spaventi S and Pavelic K: Metastasis: New perspectives on an old
problem. Mol Cancer. 10:222011. View Article : Google Scholar : PubMed/NCBI
|
